Close
Help





JOURNAL

Clinical Medicine Reviews in Vascular Health

Apixaban for the Prevention of Thromboembolism in Adults after Elective Hip or Knee Replacement Surgery, and in Symptomatic Venous Thromboembolism

Submit a Paper


Clinical Medicine Reviews in Vascular Health 2012:4 19-28

Review

Published on 21 Mar 2012

DOI: 10.4137/CMRVH.S7280


Further metadata provided in PDF

Download Article PDF


Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Vascular Health

Abstract

The anticoagulant effect of apixaban is due to direct inhibition of FXa in the coagulation cascade. The main advantages apixaban has over the current anti-coagulant drugs is that it is active after oral administration, and its coagulation effect does not require monitoring. Apixaban has been compared to enoxaparin in the prevention of venous thromboembolism associated with knee and hip replacement, where it is as efficacious as enoxaparin, but causes less bleeding. However, apixaban is not the only FXa inhibitor that could replace enoxaparin for this indication, as the FXa inhibitor rivaroxaban is as efficacious and safe as enoxaparin in preventing thromboembolism associated with these surgical procedures. Until the results of the AMPLIFY Phase III trial are known, it is too early to consider apixaban as an alternative to enoxaparin in symptomatic thromboembolism. Apixaban should not be used to prevent thromboembolism in medical immobilised subjects or acute coronary syndromes, as it causes excess bleeding in these conditions without benefit.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services